Kidney Disease - Pipeline Review, H1 2014
This report provides comprehensive information on the therapeutic development fo...
chemocentryx, Inc. 36
anexon, Inc. 37
otsuka Holdings Co., Ltd. 38
bioprojet Scr 39
advicenne Pharma 40
zs Pharma, Inc. 41...
product Description 71
mechanism Of Action 71
r&d Progress 71
rg-7641 - Drug Profile 72
product Description 72
mechanism O...
product Description 88
mechanism Of Action 88
r&d Progress 88
a77-based Monobody - Drug Profile 89
product Description 89
...
Upcoming SlideShare
Loading in...5
×

Kidney disease pipeline review, h1 2014

80

Published on

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
80
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Transcript of "Kidney disease pipeline review, h1 2014"

  1. 1. Kidney Disease - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Kidney Disease and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Kidney Disease The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Kidney Disease and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Kidney Disease Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Kidney Disease pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 kidney Disease Overview 10 therapeutics Development 11 pipeline Products For Kidney Disease Overview 11 pipeline Products For Kidney Disease Comparative Analysis 12 kidney Disease Therapeutics Under Development By Companies 13 kidney Disease Therapeutics Under Investigation By Universities/institutes 16 kidney Disease Pipeline Products Glance 17 late Stage Products 17 clinical Stage Products 18 early Stage Products 19 kidney Disease Products Under Development By Companies 20 kidney Disease Products Under Investigation By Universities/institutes 21 kidney Disease Companies Involved In Therapeutics Development 22 f. Hoffmann-la Roche Ltd. 22 sanofi 23 nektar Therapeutics 24 chugai Pharmaceutical Co., Ltd. 25 leo Pharma A/s 26 teva Pharmaceutical Industries Limited 27 zydus Cadila Healthcare Limited 28 gentium S.p.a. 29 celldex Therapeutics, Inc. 30 osteologix Holdings Plc. 31 ahn-gook Pharmaceutical Co., Ltd. 32 diamedica Inc. 33 upsher-smith Laboratories, Inc. 34 tetralogic Pharmaceuticals 35 Kidney Disease - Pipeline Review, H1 2014
  2. 2. chemocentryx, Inc. 36 anexon, Inc. 37 otsuka Holdings Co., Ltd. 38 bioprojet Scr 39 advicenne Pharma 40 zs Pharma, Inc. 41 g1 Therapeutics, Inc. 42 abbvie Inc. 43 kidney Disease Therapeutics Assessment 44 assessment By Monotherapy Products 44 assessment By Target 45 assessment By Mechanism Of Action 48 assessment By Route Of Administration 51 assessment By Molecule Type 53 drug Profiles 55 adv-7809 - Drug Profile 55 product Description 55 mechanism Of Action 55 r&d Progress 55 benazepril Hydrochloride - Drug Profile 56 product Description 56 mechanism Of Action 56 r&d Progress 56 adv-7103 - Drug Profile 57 product Description 57 mechanism Of Action 57 r&d Progress 57 tolvaptan - Drug Profile 58 product Description 58 mechanism Of Action 58 r&d Progress 58 methylprednisolone - Drug Profile 60 product Description 60 mechanism Of Action 60 r&d Progress 60 zs-9 - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 agnpn-803 - Drug Profile 62 product Description 62 mechanism Of Action 62 r&d Progress 62 hydrocodone Bitartrate Er - Drug Profile 63 product Description 63 mechanism Of Action 63 r&d Progress 63 leo-27847 - Drug Profile 65 product Description 65 mechanism Of Action 65 r&d Progress 65 dm-199 - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 tiprolisant - Drug Profile 67 product Description 67 mechanism Of Action 67 r&d Progress 67 abt-614 - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 anx-042 - Drug Profile 70 product Description 70 mechanism Of Action 70 r&d Progress 70 ccx-872 - Drug Profile 71 Kidney Disease - Pipeline Review, H1 2014
  3. 3. product Description 71 mechanism Of Action 71 r&d Progress 71 rg-7641 - Drug Profile 72 product Description 72 mechanism Of Action 72 r&d Progress 72 cdx-1189 - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 cu-np - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 necrostatin Program - Drug Profile 75 product Description 75 mechanism Of Action 75 r&d Progress 75 oligotide - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 nktr-228 - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 ccr2 Antagonist - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 ch-5451098 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 skqr-1 - Drug Profile 80 product Description 80 mechanism Of Action 80 r&d Progress 80 tnt-009 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 slr-080811 Derivative - Drug Profile 82 product Description 82 mechanism Of Action 82 r&d Progress 82 ave-0991 - Drug Profile 83 product Description 83 mechanism Of Action 83 r&d Progress 83 nbs-101 - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 prod-1 - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 messenger Rna Therapeutics Program - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 ahro-200 - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 cdk-4/6 Inhibitors As Renal Protectants - Drug Profile 88 Kidney Disease - Pipeline Review, H1 2014
  4. 4. product Description 88 mechanism Of Action 88 r&d Progress 88 a77-based Monobody - Drug Profile 89 product Description 89 mechanism Of Action 89 r&d Progress 89 kidney Disease Recent Pipeline Updates 90 kidney Disease Dormant Projects 98 kidney Disease Product Development Milestones 99 featured News & Press Releases 99 nov 07, 2013: La Jolla Pharmaceutical Company Presents Data At The Annual American Society Of Nephrology Conference 99 may 02, 2013: Arena Pharma Withdraws European Marketing Authorization Application For Belviq 99 mar 28, 2013: Cytori Therapeutics Receives Us Patent Covering Method Of Treating Renal Diseases Using Adipose-derived Regenerative Cells 99 jan 08, 2013: Medicure Announces Filing Of Snda For Aggrastat Label Change 100 nov 06, 2012: Lexicon Pharma Presents Phase Iib Results Of Lx4211 At American Heart Association Annual Conference 101 oct 17, 2012: Raptor Pharma Announces Presentation Of Procysbi Extension Study Data At American Society Of Nephrology Annual Meeting 102 aug 03, 2012: New Published Data Demonstrate Endocyte's Targeted Small Molecule Drug Conjugate Approach Shows Promising Results In Polycystic Kidney Disease Model 102 mar 05, 2012: Medistem To Begin Clinical Trials Using Erc Stem Cells For Renal, Lung And Peripheral Artery Disease 103 may 11, 2011: Rockwell Medical Receives Us Patent For Sfp Packaging And Method Of Use 104 appendix 105 methodology 105 coverage 105 secondary Research 105 primary Research 105 expert Panel Validation 105 contact Us 106 disclaimer 106 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Kidney Disease - Pipeline Review, H1 2014

×